;){kind=link}
Mr. Hommer
Manager
Sales Department
Address:
No. 62, Gaoxin Avenue, Nanning, Guangxi, China
Telephone:
Zip Code:
Fax:
| Please sign in to view contact details |
Account Registered in:
2012
Business Range:
Agriculture & Food, Health & Medicine, Light Industry & Daily Use
Management System Certification:
ISO 9001
Business Type:
Manufacturer/Factory, Trading Company
Company Introduction
Trade Capacity
Production Capacity
Sinozyme Biotechnology Co., Ltd. Nanning Profile
Sinozyme Biotechnology Co., Ltd. Nanning is a high-tech enterprise established in 2001, focusing on the research, production and application of trehalose for more than 20 years, with a number of trehalose production and application patents, is the earliest large-scale production of trehalose enterprises in China, and is also the drafting unit of ...
Sinozyme Biotechnology Co., Ltd. Nanning is a high-tech enterprise established in 2001, focusing on the research, production and application of trehalose for more than 20 years, with a number of trehalose production and application patents, is the earliest large-scale production of trehalose enterprises in China, and is also the drafting unit of ...
Sinozyme Biotechnology Co., Ltd. Nanning Profile
Sinozyme Biotechnology Co., Ltd. Nanning is a high-tech enterprise established in 2001, focusing on the research, production and application of trehalose for more than 20 years, with a number of trehalose production and application patents, is the earliest large-scale production of trehalose enterprises in China, and is also the drafting unit of China's trehalose national standard (GB/T23529-2009).
Sinozyme has a high-level scientific and technological and management team, and the professional and technical quality of employees is excellent. The business model, management system, customer service, etc. Are strictly operated in accordance with the modern enterprise system. The company has established comprehensive laboratories and pilot bases that are compatible with R&D technology and production technology, and has a good long-term technical cooperative relationship with scientific research institutions such as Guangxi Academy of Sciences, Guangxi University, Nanjing University and so on. The company has 3 on-the-job doctors, 5 part-time doctors, more than 20 trehalose-related patents and other patents, and established an "academician workstation" in 2017.
Sinozyme "bioengineering enzymatic conversion of tapioca starch to produce trehalose" national high-tech industrialization demonstration project is the first to open the industrialization of trehalose, with original process technology, advanced equipment in line with international pharmaceutical standards, complete biochemical product testing instruments and perfect quality management system, to produce high-quality trehalose products. In January 2023, trehalose produced by our company obtained the registration number of pharmaceutical excipients from the Center for Drug Evaluation of the State Medical Products Administration, and the product quality reached a new level.
Sinozyme according to the national standard production of trehalose products with three specifications, its technical indicators can meet the needs of different customer groups, the product capacity is as follows: First-class crystalline trehalose 1000 tons/year, Pharmaceutical grade trehalose dihydrate 100 tons/year, Pharmaceutical grade trehalose is anhydrous 20 tons/year.
Sinozyme Biotechnology Co., Ltd. Nanning is a high-tech enterprise established in 2001, focusing on the research, production and application of trehalose for more than 20 years, with a number of trehalose production and application patents, is the earliest large-scale production of trehalose enterprises in China, and is also the drafting unit of China's trehalose national standard (GB/T23529-2009).
Sinozyme has a high-level scientific and technological and management team, and the professional and technical quality of employees is excellent. The business model, management system, customer service, etc. Are strictly operated in accordance with the modern enterprise system. The company has established comprehensive laboratories and pilot bases that are compatible with R&D technology and production technology, and has a good long-term technical cooperative relationship with scientific research institutions such as Guangxi Academy of Sciences, Guangxi University, Nanjing University and so on. The company has 3 on-the-job doctors, 5 part-time doctors, more than 20 trehalose-related patents and other patents, and established an "academician workstation" in 2017.
Sinozyme "bioengineering enzymatic conversion of tapioca starch to produce trehalose" national high-tech industrialization demonstration project is the first to open the industrialization of trehalose, with original process technology, advanced equipment in line with international pharmaceutical standards, complete biochemical product testing instruments and perfect quality management system, to produce high-quality trehalose products. In January 2023, trehalose produced by our company obtained the registration number of pharmaceutical excipients from the Center for Drug Evaluation of the State Medical Products Administration, and the product quality reached a new level.
Sinozyme according to the national standard production of trehalose products with three specifications, its technical indicators can meet the needs of different customer groups, the product capacity is as follows: First-class crystalline trehalose 1000 tons/year, Pharmaceutical grade trehalose dihydrate 100 tons/year, Pharmaceutical grade trehalose is anhydrous 20 tons/year.
International Commercial Terms(Incoterms):
FOB, FCA
Terms of Payment:
LC, T/T
Export Year:
2004-03-18
Export Percentage:
21%~30%
Main Markets:
North America, South America, Eastern Europe, Southeast Asia, Africa, Oceania, Mid East, Eastern Asia, Western Europe
Import & Export Mode:
Have Own Export License
Factory Address:
No. 62, Gaoxin Avenue, Nanning, Guangxi, China
R&D Capacity:
OEM
No. of R&D Staff:
5-10 People
No. of Production Lines:
2
Annual Output Value:
Above US$100 Million